Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-sensitive ovarian cancer (OC): CALYPSO study of the Gynecologic Cancer Intergroup (GCIG)

(2017) E. Pujade-Lauraine et al.   JOURNAL OF CLINICAL ONCOLOGY

Changing the Paradigm in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer

(2010) Bradley J. Monk et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

(2010) Bradley J. Monk et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

(2009) J. M. Del Campo et al.   ANNALS OF ONCOLOGY

18LBA A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients

(2009) P. Vasey et al.   EJC SUPPLEMENTS

A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies

(2008) M. von Mehren et al.   ANNALS OF ONCOLOGY

Phase I Combination Study of Trabectedin and Doxorubicin in Patients with Soft-Tissue Sarcoma

(2008) J.-Y. Blay et al.   CLINICAL CANCER RESEARCH

Management of partially platinum-sensitive relapsed ovarian cancer

(2008) Stanley B. Kaye   EJC SUPPLEMENTS

Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer

(2008) C. Sessa et al.   EUROPEAN JOURNAL OF CANCER

Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer

(2007) A. GADDUCCI et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER